About this event

Are you interested in translating your antibody research into impactful therapeutics for patients?

LifeArc is actively seeking partnerships with early-stage innovators from King's College London. Join us to hear about LifeArc's unique collaboration model, enabling access to their antibody discovery and humanisation platforms at no cost while retaining full IP ownership and commercialisation control.

Over the past 30 years, LifeArc has humanised 94 antibodies, five of which have been approved as medicines, including some of the world’s top-selling antibody products, such as Keytruda® (pembrolizumab) and Entyvio® (vedolizumab). Together with the recently launched B-SMArT (B-cell Screening Method for Antibody Therapeutics) antibody discovery platform, which includes a clinically validated transgenic mouse and innovative single B-cell-based screening technologies; LifeArc provides comprehensive developability assessments and delivers fully human antibodies ready for preclinical development, helping to bring new and innovative treatment options to patients.

Register now for your place to learn more and network with others working in this area.

Please also contact our expert Translational Research Managers who can provide further information and help:

Dr Mike Lyne – mike.lyne@kcl.ac.uk – Drug Development

Dr Lisa Harper – lisa.harper@kcl.ac.uk – Mental Health and Neuroscience

Dr Julian Dye – julian.dye@kcl.ac.uk – Advanced Therapies and MedTech

Dr Cathy Boucher – cathy.boucher@kcl.ac.uk – Therapeutics and MedTech